Next Generation Cancer Diagnostics Market Size, Share, By Technology (Protein Microarrays, Next Generation Sequencing, DNA Microarrays, qPCR & Multiplexing, and Others), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other Cancer Types), By Function (Risk Analysis, Prognostics, Therapeutics Monitoring, Cancer Screening, and Companion Diagnostics), By Application (CTC Analysis, Biomarker Development, Proteomic Analysis and Others), and By Region - Trends, Analysis and Forecast till 2034

Next Generation Cancer Diagnostics Market Size was valued at USD 18.4 billion in 2024 and is expected to grow at a CAGR of 9.5% to reach USD 42.0 billion by 2034.

Next Generation Cancer Diagnostics represents a transformative leap in the detection, diagnosis, and monitoring of cancer. Leveraging advanced technologies, NGCD provides more accurate, timely, and personalized insights into cancer than traditional methods. This new era of cancer diagnostics is characterized by its ability to analyze genetic, epigenetic, proteomic, and cellular data, offering a comprehensive understanding of the disease at a molecular level.

Biopsies, histological examination, and imaging methods have long been used in the diagnosis of cancer. Although these techniques have proven invaluable in the detection and management of cancer, they frequently have drawbacks such invasiveness, a lack of specificity, and delayed results. These issues are addressed by the development of next-generation technologies, which offer more accurate diagnoses that can identify cancer early, forecast its course, and customize treatment regimens based on a patient's genetic composition.

In the age of precision medicine where therapies are more closely matched to the genetic profile of the patient's tumor, next generation cancer diagnostics is essential. These diagnostics lessen the trial-and-error process of traditional treatments by helping clinicians select medications that are more likely to be successful by recognizing particular biomarkers. This tailored strategy reduces the possibility of negative consequences while simultaneously improving patient results.

Key Drivers of Target Market:

Advancements in Liquid Biopsy Technology

• Early identification of genetic alterations linked to cancer is made possible by liquid biopsy in certain cases, this is even possible before clinical signs manifest. Additionally, it enables real-time tracking of the course of cancer and how it responds to therapy, providing dynamic insights into the illness.
• For instance, in July 2024, a breakthrough in liquid biopsy technology was announced by Guardant Health, enabling the detection of multiple cancers from a single blood sample. This development underscores the growing potential of liquid biopsies as a key driver in early cancer detection and personalized treatment.
• The adoption of liquid biopsy is rapidly increasing across the healthcare industry, driven by its non-invasive nature and the growing emphasis on early detection and personalized medicine. This factor is expected to continue as more healthcare providers recognize the benefits of incorporating liquid biopsy into standard diagnostic practices.

Rising Government and Private Sector Investments

• Governments and private organizations are increasingly investing in cancer research and diagnostic technologies fueling the target market growth. Further, these investments are aimed at improving early detection and treatment, which are key to reducing cancer mortality rates.
• Increased funding accelerates the development and commercialization of innovative diagnostic tools bringing them to market faster. Public-private partnerships are also on the rise and further it boosts this innovation and target market expansion.

Increased Focus on Personalized Medicine

• Treatment strategies are customized by personalized medicine according to each patient's unique cancer genetic profile, which improves results. The application of personalized medicine depends heavily on developments in diagnostic technologies like NGS and biomarkers.
• For instance, in June 2024, Pfizer announced a collaboration with Foundation Medicine to develop companion diagnostics for personalized cancer treatments reinforcing the focus on precision medicine in the market.

Restrains:

Technical Complexity and Lack of Expertise

• The use of advanced diagnostics such as NGS requires specialized equipment and skilled personnel, which is a barrier to adoption in less equipped healthcare settings. The technical complexity of next-generation diagnostics means that many healthcare providers need additional training to effectively use and interpret the results. This lack of expertise can lead to misinterpretation of diagnostic results, potentially compromising patient care.

Data Privacy and Security Concerns

• The collection and analysis of genetic data raise significant privacy and security concerns particularly with the increased use of digital platforms and cloud-based systems. Patients hesitate to undergo next-generation diagnostics due to fears that their genetic information could be misused or compromised.

Opportunities:

Integration of Artificial Intelligence (AI) and Machine Learning

• AI and machine learning algorithms can analyze complex data from imaging and genomic tests to improve diagnostic accuracy and identify cancer at earlier stages. AI-driven tools can predict disease progression and treatment responses, aiding in more informed clinical decisions and personalized treatment strategies.

Growth in Genomic and Molecular Profiling

• Advanced genomic and molecular profiling enables the identification of specific genetic mutations and biomarkers, facilitating the development of targeted therapies and precision medicine. Offering comprehensive testing panels that cover a wide range of genetic and molecular markers can enhance diagnostic capabilities and cater to diverse cancer types.  

The market is segmented based on Technology, Cancer Type, Function, Application, and Region.

Technology Insights:

• Protein Microarrays: High-throughput methods for analyzing protein expressions, relationships, and functions on a broad scale are protein microarrays. They make it possible to measure thousands of proteins at once, which offers important information about cancer biomarkers and possible treatment targets.
• Next Generation Sequencing (NGS): This segment is expected to dominate the target market growth as it enables detailed examination of genetic mutations, variations, and expressions associated with cancer, facilitating precise diagnosis and treatment planning. It provides a high-resolution view of the cancer genome, allowing for personalized medicine approaches based on individual genetic profiles.
• DNA Microarrays: This segment is crucial for identifying genetic alterations and expression patterns associated with different cancer types. By comparing gene expression profiles between cancerous and normal tissues, researchers can identify biomarkers and understand tumor biology.
• qPCR & Multiplexing: Multiplexing enhances qPCR by allowing the simultaneous detection of multiple targets in a single reaction. This technology is widely used for its sensitivity, accuracy, and ability to detect low-abundance biomarkers in cancer diagnostics.  
• Other: This segment includes various other diagnostic technologies and methodologies not covered by the primary categories. This may include advanced imaging techniques, proteomics, metabolomics, and emerging diagnostic platforms that offer additional insights into cancer detection and characterization.

Cancer Type Insights:

• Lung Cancer: Due to the high incidence rate and significant research investments, lung cancer diagnostics are a major focus in the target market. Lung cancer diagnostics are advancing with next-generation techniques focusing on early detection through advanced imaging, liquid biopsies, and genomic profiling.
• Breast Cancer: Breast cancer diagnostics have seen substantial advancements, including the use of high-resolution imaging, genetic testing, and advanced biomarkers. These methods aim to improve early detection and tailor treatment strategies as this segment is expected to dominate the target market growth.
• Colorectal Cancer: Next-generation diagnostics for colorectal cancer focus on early detection through advanced screening techniques, including molecular diagnostics and non-invasive stool tests. These methods aim to enhance early diagnosis and reduce mortality rates.
• Cervical Cancer: Cervical cancer diagnostics are crucial due to the effectiveness of early screening programs and vaccination efforts.    
• Other Cancer Types: This segment includes diagnostics for cancers such as prostate, ovarian and pancreatic. Next-generation diagnostics are focusing on personalized approaches including genomics and proteomics to improve detection and treatment.  

Function Insights:

• Risk Analysis: Risk analysis in the target market involves assessing the likelihood of developing cancer based on genetic, environmental, and lifestyle factors. Advanced diagnostic technologies, such as genomic profiling and bioinformatics tools, enable a comprehensive risk assessment.  
• Prognostics: This segment focuses on predicting the likely course and outcome of cancer after diagnosis. It involves using advanced diagnostic tools to assess disease progression, response to treatment, and potential recurrence. Techniques such as molecular profiling, liquid biopsies, and imaging technologies provide insights into tumor behavior and patient prognosis.
• Therapeutics Monitoring: Therapeutics monitoring involves tracking the effectiveness of cancer treatments through advanced diagnostic methods. This includes monitoring changes in biomarkers, imaging results, and molecular profiles to assess how well the therapy is working.  
• Cancer Screening: Next-generation cancer diagnostics enhance screening methods through technologies like liquid biopsies, advanced imaging, and molecular tests that identify cancer-related biomarkers. These innovative approaches improve the sensitivity and specificity of screenings, allowing for earlier and more accurate detection of various cancers and also this segment is expected to dominate the target market growth.   
• Companion Diagnostics: Tests known as companion diagnostics are intended to help cancer patients make individualized treatment decisions. They find particular genetic variants or biomarkers that indicate a patient's propensity to respond favorably to a given treatment.

Application Insights:

• CTC Analysis: Finding and measuring tumour cells that are floating about in the bloodstream is the goal of CTC analysis. This non-invasive technique aids in the early detection of cancer, tracking the course of the illness, and evaluating the effectiveness of treatment.
• Biomarker Development: This segment is expected to dominate the target market growth as it focuses on identifying specific biological markers that indicate the presence or progression of cancer. These biomarkers can be proteins, nucleic acids, or other molecules that reflect changes associated with cancer.   
• Proteomic Analysis: Analyzing all of the proteins expressed in cancer cells, tissues, or body fluids is known as proteomic analysis. Researchers can find alterations linked to the onset and spread of cancer by examining protein patterns.  
• Others: This segment category includes various diagnostic technologies and methods not covered by the primary segments. This can encompass genetic testing, imaging techniques, liquid biopsy technologies, and advanced molecular diagnostics. Each of these methods contributes to the broader field of cancer diagnostics by providing additional tools for detecting, monitoring, and managing cancer. 

Regional Insights

• North America: This region is known for early adoption of new technologies and innovations in cancer diagnostics. The United States and other countries in North America dominate the market for next-generation cancer diagnostics because of their highly invested in research and development as well as their sophisticated healthcare infrastructure.
• Asia Pacific: This region is rapidly growing in the Next Generation Cancer Diagnostics Market, driven by increasing healthcare investments and a large patient population. Rising awareness about cancer and improvements in healthcare infrastructure are expanding market opportunities.
• Europe: Advanced healthcare systems and a focus on improving diagnostic accuracy contribute to target market growth. European countries are home to several prominent research institutions and biotech firms specializing in cancer diagnostics.
• Latin America: Next Generation Cancer Diagnostics Market in Latin America is in a growth phase, with increasing adoption of advanced diagnostic technologies.
• Middle East and Africa: Increased investments in healthcare infrastructure and cancer research are supporting market growth. Rising cancer incidence and the need for advanced diagnostic tools are driving demand in this region.

Next Generation Cancer Diagnostics Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Technology, Cancer Type, Function, Application, and Region.

By Technology:

• Protein Microarrays
• Next Generation Sequencing
• DNA Microarrays
• qPCR & Multiplexing
• Others

By Cancer Type:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Other Cancer Types

By Function:

• Risk Analysis
• Prognostics
• Therapeutics Monitoring
• Cancer Screening
• Companion Diagnostics

By Application:

• CTC Analysis
• Biomarker Development
• Proteomic Analysis
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Next Generation Cancer Diagnostics Market include Koninklijke Philips N.V., Illumina, Inc., F. Hoffmann-La Roche Ltd, Qiagen, Cepheid, Novartis AG, Abbott, Thermo Fisher Scientific, Inc., Sysmex Corporation, Opko Health, Inc., Myriad Genetics, Inc., Agilent Technologies, GE Healthcare, PerkinElmer, Inc., Genomic Health, Inc., Hologic, Inc., Almac Group, and Janssen Global Services, LLC.  

• In June 2024, personalized cancer treatment is being advanced in clinical oncology with the increasing application of next-generation sequencing (NGS). The use of NGS is booming in India thanks to technological developments, which are also improving patient care by directing more precise and focused screening as well as targeted treatments.

• Koninklijke Philips N.V.*
  • Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Qiagen
• Cepheid
• Novartis AG
• Abbott
• Thermo Fisher Scientific, Inc.
• Sysmex Corporation
• Opko Health, Inc.
• Myriad Genetics, Inc.
• Agilent Technologies
• GE Healthcare
• PerkinElmer, Inc.
• Genomic Health, Inc.
• Hologic, Inc.
• Almac Group
• Janssen Global Services, LLC

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Technology
  • Market Snippet, By Cancer Type
  • Market Snippet, By Function
  • Market Snippet, By Application
  • Market Snippet, By Region
• Opportunity Map Analysis

1. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Market Trends
   • Technology Launch
   • Merger and Acquisitions
   • Impact Analysis
   • PEST Analysis
   • Porter’s Analysis

Market Segmentation, By Technology, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Protein Microarrays
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Next Generation Sequencing
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• DNA Microarrays
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• qPCR & Multiplexing
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, By Cancer Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Lung Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Breast Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Colorectal Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Cervical Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Other Cancer Types
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, By Function, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Risk Analysis
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Prognostics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Therapeutics Monitoring
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Cancer Screening
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Companion Diagnostics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, By Application, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• CTC Analysis
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Biomarker Development
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Proteomic Analysis
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Technology, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Function, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Technology, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Function, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Bn), By Technology, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Function, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Bn), By Technology, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Function, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Bn), By Technology, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Function, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Koninklijke Philips N.V.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Qiagen
• Cepheid
• Novartis AG
• Abbott
• Thermo Fisher Scientific, Inc.
• Sysmex Corporation
• Opko Health, Inc.
• Myriad Genetics, Inc.
• Agilent Technologies
• GE Healthcare
• PerkinElmer, Inc.
• Genomic Health, Inc.
• Hologic, Inc.
• Almac Group
• Janssen Global Services, LLC

The Last Word

• Future Impact
• About Us
• Contact